Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy
Brief Summary: This randomized study will compare maintenance therapy with Avastin (bevacizumab) + Xeloda (capecitabine) versus Avastin alone, in patients with HER2-negative metastatic breast cancer who have not progressed during first-line therapy with docetaxel + Avastin. Eligible patients will receive up to 6 x 3 week cycles of treatment with Avastin (15 mg/mg IV on Day 1 of each cycle) + docetaxel (75-100 mg/m2 IV on Day 1 of each cycle). Those patients who do not progress will be randomized to 3 week cycles of either a) Avastin (15 mg/kg IV on Day 1 of each cycle) + Xeloda (1000 mg/m2 po bid on Days 1-14 of each cycle) or b) Avastin alone. Study treatment will continue until disease progression, unacceptable toxicity, patient request for withdrawal or end of study, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Epi-CMF; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: epirubicin hydrochloride, Drug: fluorouracil, Drug: methotrexate, Procedure: adjuvant therapy | Arm Label: Accelerated Epi-CMF; Type: EXPERIMENTAL; Interventions: Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: epirubicin hydrochloride, Drug: fluorouracil, Drug: methotrexate, Procedure: adjuvant therapy | Arm Label: Epi-Capecitabine; Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Drug: epirubicin hydrochloride, Procedure: adjuvant therapy | Arm Label: Accelerated Epi-Capecitabine; Type: EXPERIMENTAL; Interventions: Biological: pegfilgrastim, Drug: capecitabine, Drug: epirubicin hydrochloride, Procedure: adjuvant therapy | Intervention Type: BIOLOGICAL; Name: pegfilgrastim; Assigned to Arm(s): Accelerated Epi-CMF, Accelerated Epi-Capecitabine | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Accelerated Epi-Capecitabine, Epi-Capecitabine | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Accelerated Epi-CMF, Epi-CMF | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): Accelerated Epi-CMF, Accelerated Epi-Capecitabine, Epi-CMF, Epi-Capecitabine | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Accelerated Epi-CMF, Epi-CMF | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Accelerated Epi-CMF, Epi-CMF | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): Accelerated Epi-CMF, Accelerated Epi-Capecitabine, Epi-CMF, Epi-Capecitabine
B: Arm Label: Avastin (bevacizumab); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab [Avastin] | Arm Label: Avastin (bevacizumab) + Xeloda (capecitabine); Type: EXPERIMENTAL; Interventions: Drug: bevacizumab [Avastin], Drug: capecitabine [Xeloda] | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): Avastin (bevacizumab), Avastin (bevacizumab) + Xeloda (capecitabine) | Intervention Type: DRUG; Name: capecitabine [Xeloda]; Assigned to Arm(s): Avastin (bevacizumab) + Xeloda (capecitabine)
C: Intervention Type: BIOLOGICAL; Name: trastuzumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: E7389 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physician's Choice | Intervention Type: DRUG; Name: E7389; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Physician's Choice; Assigned to Arm(s): 2

Answer: B